Finding a gastric cancer trial that fits your treatment history

Build a one-page clinical profile

Include gastric or gastroesophageal junction adenocarcinoma, stage, surgery history and where the cancer is measurable now. Add each systemic regimen, its dates, best response and the reason it stopped. Distinguish treatment around surgery from treatment for metastatic disease.

List HER2, PD-L1 CPS, MSI/MMR and CLDN18.2 results with the laboratory dates. Add other sequencing findings where available. The full reports should accompany the summary because a trial may require a particular assay, staining threshold or mutation type.

Sources and references: [1] [2]

Match the study to the decision you face

Some studies concern treatment before an operation; others enroll people starting first-line advanced-disease treatment or those whose disease has progressed after specified drugs. A trial described as gastric cancer research may therefore be irrelevant to your current decision.

Ask what the study is trying to improve and what treatment you would receive outside it. An early-phase dose study and a randomized comparison of treatment strategies answer different questions. The practical discussion should reflect that difference, including the degree of uncertainty and the monitoring burden.

Sources and references: [2]

Check the exact biomarker requirement

A HER2-targeted study may have different entry criteria from a CLDN18.2-directed study. Some exclude previous treatment against the same target, while others are designed specifically for resistance. A PD-L1-positive label without the numerical CPS may be insufficient for screening.

Ask whether the study team will accept the existing tissue and testing or needs a new biopsy or central review. Clarify the time and costs involved. If several studies seem suitable, the order of treatments may affect which options remain possible later.

Sources and references: [2] [1]

Separate a published trial from an open place

Search registries using the disease, biomarker and drug names, then review the specific location and recruitment details. A registry can identify a possible study, but the site team needs to confirm that it is screening the relevant cohort and has capacity.

Keep the study identifier with your notes. Ask who can review the records and which criteria commonly exclude patients, such as prior therapies, organ function or performance status. Treat a preliminary record review as a step toward formal screening, with the site making the eligibility decision.

Sources and references: [2]

Recheck whether the treatment is still trial-only

Treatment status can change while a patient is searching. For example, China approved satri-cel in June 2026 for a defined CLDN18.2-positive, HER2-negative advanced gastric/GEJ population after at least two prior treatment lines. An older article may still describe that entire route as experimental.

Ask whether the option being discussed is an approved product used within its indication, an off-label strategy or a study of a different product or setting. That determines the consent process, access route, costs and follow-up requirements. The treating team should explain the distinction using the actual proposed regimen.

Sources and references: [3] [4]

Read the commitments before deciding

Discuss randomization, the comparison group, biopsies, extra blood tests and the visit schedule. Ask which tests and treatments the study pays for and which costs remain yours. Caregiver time, accommodation and repeat travel can be important parts of the decision.

Ask what happens if the cancer grows, a side effect develops or you choose to withdraw. You should understand how urgent care will be provided and how the team will communicate with your regular oncologist. Take time to read the consent material in a language you understand.

Sources and references: [2]

Keep a safe plan during screening

Screening can involve repeat scans, laboratory tests or waiting for tissue review. Ask your oncologist how much time is reasonable in your current condition and what treatment or symptom support should continue meanwhile. A study may require a defined interval after previous therapy, which needs clinical planning.

Maintain a backup plan if eligibility is not confirmed. For patients with worsening intake, bleeding or obstruction, symptom treatment may be more urgent than a distant trial visit. Ask the trial team which evaluations can be completed locally before making a major travel commitment.

Sources and references: [1] [2]

Coordinating a Shanghai trial inquiry

Fudan University Shanghai Cancer Center has gastric cancer clinical and research services. Our hospital profile is a starting point for an inquiry; the specific study and site team need to confirm current screening arrangements.

EastMedGo can help organize the records and communicate practical questions about a proposed study or consultation. Send the study identifier, biomarker reports and treatment timeline through contact. We can help clarify document requirements and visit logistics while the clinical team assesses fit and discusses the alternatives.

Sources and references: [5] [2]

Common questions